Avenue Therapeutics Inc. (NASDAQ:ATXI) shares traded -1.89% lower at $1.04 on Wall Street last session.
In accordance with the data, 1 analysts cover Avenue Therapeutics Inc. (NASDAQ:ATXI). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $32.00 and a low of $32.00, we find $32.00. Given the previous closing price of $1.06, this indicates a potential upside of 2918.87 percent. ATXI stock price is now -18.43% away from the 50-day moving average and -65.29% away from the 200-day moving average. The market capitalization of the company currently stands at $5.69M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $32.00 as their price target over the next twelve months.
In other news, InvaGen Pharmaceuticals, Inc., 10% Owner sold 388,888 shares of the company’s stock on Oct 11. The stock was sold for $2,999,882 at an average price of $7.71. Upon completion of the transaction, the 10% Owner now directly owns 0 shares in the company, valued at $0.0. Insiders disposed of 388,888 shares of company stock worth roughly $0.4 million over the past 1 year. A total of 17.34% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ATXI stock. A new stake in Avenue Therapeutics Inc. shares was purchased by SABBY MANAGEMENT, LLC during the first quarter worth $280,000. BANK OF NEW YORK MELLON CORP invested $57,000 in shares of ATXI during the first quarter. In the first quarter, QUBE RESEARCH & TECHNOLOGIES LTD acquired a new stake in Avenue Therapeutics Inc. valued at approximately $50,000. VIRTU FINANCIAL LLC acquired a new stake in ATXI for approximately $35,000. GEODE CAPITAL MANAGEMENT, LLC purchased a new stake in ATXI valued at around $12,000 in the second quarter. In total, there are 14 active investors with 1.60% ownership of the company’s stock.
Avenue Therapeutics Inc. (NASDAQ: ATXI) opened at $1.0300 on Wednesday. During the past 12 months, Avenue Therapeutics Inc. has had a low of $0.98 and a high of $16.65. The fifty day moving average price for ATXI is $1.2750 and a two-hundred day moving average price translates $2.9966 for the stock.
The latest earnings results from Avenue Therapeutics Inc. (NASDAQ: ATXI) was released for Sep, 2022.
Avenue Therapeutics Inc.(ATXI) Company Profile
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Leave a Reply